Skip to main content
GSK
NYSE Life Sciences

GSK Announces Positive Phase 3 Results for Bepirovirsen in Chronic Hepatitis B, Meeting Primary Endpoints

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$50.59
Mkt Cap
$103.44B
52W Low
$31.715
52W High
$51.46
52W Position info
60% above low
Off High info
1.7% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

GSK sits 60% above its 52-week low of $31.715.

Summary

GSK reported positive Phase III trial results for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B, demonstrating statistically significant functional cure rates and paving the way for global regulatory filings.


Key Events · Product Development and Regulatory · GSK

  • Positive Phase III Trial Results

    Bepirovirsen met primary endpoints in the B-Well 1 and B-Well 2 pivotal Phase III trials for chronic hepatitis B (CHB).

  • Significant Functional Cure Rate Achieved

    The drug demonstrated a statistically significant and clinically meaningful functional cure rate, a critical goal for CHB patients where current treatments offer low cure rates.

  • Potential First-in-Class Treatment

    Bepirovirsen is positioned as a potential first-in-class, finite (six-month) therapeutic option for CHB, with an acceptable safety and tolerability profile.

  • Global Regulatory Filings Planned

    GSK plans to submit for global regulatory approvals starting in Q1 2026 based on these positive results, aiming to address a major global health challenge.


Analysis · GSK · Life Sciences

GSK's investigational antisense oligonucleotide, bepirovirsen, achieved statistically significant and clinically meaningful functional cure rates in two pivotal Phase III trials for chronic hepatitis B (CHB). This represents a major advancement in treating CHB, a condition affecting over 250 million people globally with limited current functional cure options. The positive data supports planned global regulatory submissions from Q1 2026, positioning bepirovirsen as a potential first-in-class, finite treatment option and a backbone for future therapies. This significantly de-risks the drug's path to market and could be a substantial revenue driver for GSK.

How filings like this one have moved

In the 30 days to Nov 8, 2026, 50.5% of the 200 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.79%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GSK was trading at $50.59 on NYSE in the Life Sciences sector, with a market capitalization of approximately $103.4B. The 52-week trading range was $31.72 to $51.46. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GSK - Latest Insights

GSK
Oct 28, 2026, 11:45 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $48.75
Real-time Price: $50.33 info
Change: +$1.58 (+3%) info
Market Cap: $102.023B info
GSK
Oct 28, 2026, 10:45 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $49.08
Real-time Price: $50.33 info
Change: +$1.25 (+3%) info
Market Cap: $102.023B info
GSK
Oct 28, 2026, 3:42 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $51.20
Real-time Price: $50.33 info
Change: -$0.870 (-2%) info
Market Cap: $102.023B info
GSK
Oct 26, 2026, 12:16 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $51.12
Real-time Price: $50.33 info
Change: -$0.785 (-2%) info
Market Cap: $102.023B info
GSK
Oct 26, 2026, 6:51 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $51.04
Real-time Price: $50.33 info
Change: -$0.710 (-1%) info
Market Cap: $102.023B info